2016
Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. Journal Of Clinical Sleep Medicine 2016, 12: 9-17. PMID: 26194728, PMCID: PMC4702197, DOI: 10.5664/jcsm.5382.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaOrexin receptor antagonistMean AHIRespiratory effectsSleep apneaMultiple dosesReceptor antagonistIntra-individual variabilityModerate obstructive sleep apneaEffects of suvorexantLowest effective doseSleep laboratory studiesTotal sleep timeMean SpO2Single doseRespiratory functionOxygen saturationPulse oximetryPlaceboPatientsSleep timeAHIDay 4Mean increaseSuvorexant
2015
Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease
Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respiratory Medicine 2015, 109: 416-426. PMID: 25661282, DOI: 10.1016/j.rmed.2014.12.010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAzepinesCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedOrexin Receptor AntagonistsPulmonary Disease, Chronic ObstructiveRespirationSeverity of Illness IndexSleepSleep Aids, PharmaceuticalSpirometryTreatment OutcomeTriazolesUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseSleep breathing disordersOrexin receptor antagonistPulmonary diseaseBreathing disordersReceptor antagonistModerate chronic obstructive pulmonary diseaseDay 4Effects of suvorexantModerate airflow limitationRespiratory depressant effectsApnea-hypopnea indexMaximum daily doseClinical research unitTotal sleep timeTreatment of insomniaMean AHICOPD patientsAirflow limitationHypopnea indexDaily doseMean SpO2Spirometry criteriaHypnotic medications
2008
The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease
Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep And Breathing 2008, 13: 79-84. PMID: 18584227, DOI: 10.1007/s11325-008-0196-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultComorbidityCross-Over StudiesDouble-Blind MethodFemaleHumansIndenesMaleOximetryPolysomnographyPulmonary Disease, Chronic ObstructiveReceptors, MelatoninSeverity of Illness IndexSleep Apnea SyndromesSleep Apnea, ObstructiveSleep Initiation and Maintenance DisordersSleep StagesYoung AdultConceptsSevere chronic obstructive pulmonary diseaseChronic obstructive pulmonary diseaseEffects of ramelteonObstructive pulmonary diseasePulmonary diseaseMean SaO2Respiratory depressant effectsApnea-hypopnea indexPoor sleep qualityTotal sleep timeMelatonin receptor agonistResultsNo significant differencesSignificant differencesAbnormal breathing eventsRamelteon 8Primary endpointAdverse eventsPersistent sleepCrossover studyDepressant effectPolysomnographic monitoringReceptor agonistRespiratory effortInsomnia treatmentSleep quality
2007
Effect of Ramelteon, a selective MT1/MT2-receptor agonist, on respiration during sleep in mild to moderate COPD
Kryger M, Wang-Weigand S, Zhang J, Roth T. Effect of Ramelteon, a selective MT1/MT2-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep And Breathing 2007, 12: 243-250. PMID: 18060441, DOI: 10.1007/s11325-007-0156-4.Peer-Reviewed Original ResearchConceptsModerate chronic obstructive pulmonary diseaseChronic obstructive pulmonary diseaseAbnormal breathing eventsSelective MT1/MT2 receptor agonistMT1/MT2 receptor agonistMean apnea-hypopnea indexBreathing eventsEffects of ramelteonMT2 receptor agonistSingle bedtime doseApnea-hypopnea indexObstructive pulmonary diseaseNumber of awakeningsTotal sleep timeMelatonin receptor agonistBedtime dosePlacebo groupAdverse eventsPulmonary diseaseCrossover studyPhysical examinationReceptor agonistSleep efficiencySleep durationSleep time
1999
Upper Airway Resistance Syndrome: Effect of Nasal Dilation, Sleep Stage, and Sleep Position
Bahammam A, Tate R, Manfreda J, Kryger M. Upper Airway Resistance Syndrome: Effect of Nasal Dilation, Sleep Stage, and Sleep Position. Sleep 1999, 22: 592-598. PMID: 10450594, DOI: 10.1093/sleep/22.5.592.Peer-Reviewed Original ResearchConceptsUpper airway resistance syndromeStage 1 sleepSleep positionNasal dilationDesaturation timeSleep architectureExternal nasal dilationArousal indexCardiorespiratory parametersSleep stagesNREM sleepNasal cross-sectional areaExternal nasal dilatorSlow-wave sleepObstructive sleepAirway collapsibilityConsecutive patientsNasal dilatorNasal obstructionResistance syndromeSupine positionIntrapharyngeal pressureIndirect markerWave sleepCrossover design
1997
Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy
Broughton R, Fleming J, George C, Hill J, Kryger M, Moldofsky H, Montplaisir J, Morehouse R, Moscovitch A, Murphy W. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997, 49: 444-451. PMID: 9270575, DOI: 10.1212/wnl.49.2.444.Peer-Reviewed Original ResearchConceptsPlacebo-controlled crossover trialOnly significant adverse effectPlacebo-controlled trialExcessive daytime somnolenceMean sleep latencyPeriodic leg movementsEpworth Sleepiness ScaleDaytime sleep episodesInternational diagnostic criteriaSignificant adverse effectsHypertensive patientsMore nauseaBlood pressureDaily doseDaytime somnolenceExcessive daytimeSleep apneaCrossover trialSleep latencyModafinil 200Nocturnal sleepPatient's abilitySleepiness ScaleSleep initiationHeart rate
1996
L-DOPA/Carbidopa for Nocturnal Movement Disorders in Uremia
Walker S, Fine A, Kryger M. L-DOPA/Carbidopa for Nocturnal Movement Disorders in Uremia. Sleep 1996, 19: 214-218. PMID: 8723378, DOI: 10.1093/sleep/19.3.214.Peer-Reviewed Original ResearchConceptsL-dopa/carbidopaRestless legs syndromeSlow-wave sleepLeg movementsSleep timeTreatment of RLSMovement arousal indexNocturnal movement disordersSingle bedtime doseChronic hemodialysis patientsPeriodic limb movementsHours of sleepBedtime doseActive medicationHemodialysis patientsCrossover studyLegs syndromeUremic patientsArousal indexMovement disordersSleep disruptionFrequent dosingObjective improvementSleep disordersEffective treatment